AbbVie News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

09.09.21	Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL) Published in The Lancet (PR Newswire)
08.09.21	AbbVie to Present Data From Its Migraine Portfolio at the 2021 International Headache Congress (PR Newswire)
30.08.21	Biotech Stocks Facing FDA Decision In September 2021 (RTTNews)
24.08.21	AbbVie Announces EC Approval Of RINVOQ In Treatment Of Moderate To Severe Atopic Dermatitis (RTTNews)
24.08.21	European Commission Approves RINVOQ® (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis (PR Newswire)
18.08.21	New England Journal of Medicine Publishes 12-Week Results from Study Evaluating Atogepant for the Preventive Treatment of Migraine (PR Newswire)
09.08.21	AbbVie Launches SKYRIZI As Single-dose 150 Mg Injection - Quick Facts (RTTNews)
09.08.21	SKYRIZI® (risankizumab-rzaa) Now Available in the U.S. as a Single 150 mg Injection for Adults with Moderate to Severe Plaque Psoriasis (PR Newswire)
04.08.21	JAMA Dermatology Publishes Data Showing RINVOQ® (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) for Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Ad... (PR Newswire)
03.08.21	Abbott's Subsidiaries Agree To Pay $160 Mln To Settle Alleged False Claims To Medicare (RTTNews)
30.07.21	MÄRKTE USA/Börsen gehen mit Abschlägen ins Wochenende (Dow Jones)
30.07.21	MÄRKTE USA/Börsen mit Abschlägen - Amazon unter Druck (Dow Jones)
30.07.21	MÄRKTE USA/Uneinheitlich - Amazon belasten Technologiesektor (Dow Jones)
30.07.21	MÄRKTE USA/Gewinnmitnahmen am Ende eines erfolgreichen Börsenmonats (Dow Jones)
30.07.21	AbbVie Lifts FY Adj. Profit View (RTTNews)
30.07.21	AbbVie Q2 adjusted earnings Beat Estimates (RTTNews)
30.07.21	AbbVie Reports Second-Quarter 2021 Financial Results (PR Newswire)
30.07.21	MARKT USA/Gewinnmitnahmen an Wall Street erwartet (Dow Jones)
29.07.21	AbbVie : FDA Oks Expanded BOTOX Label To Include Eight New Muscles To Treat Upper Limb Spasticity (RTTNews)
29.07.21	FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity (PR Newswire)
28.07.21	Ausblick: AbbVie gewährt Anlegern Blick in die Bücher (finanzen.net)
27.07.21	AbbVie, Calico Again Extend Collaboration Focused On Aging And Age-Related Diseases (RTTNews)
27.07.21	AbbVie and Calico Announce Second Extension of Collaboration Focused on Aging and Age-Related Diseases (PR Newswire)
25.07.21	New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopia, a Common and Progressive Eye Condition (PR Newswire)
24.07.21	FDA Approves AbbVie's Dalvance To Treat Acute Bacterial Skin & Skin Structure Infections In Children (RTTNews)
23.07.21	DALVANCE® (dalbavancin) Receives FDA Approval to Treat Acute Bacterial Skin and Skin Structure Infections in Pediatric Patients (PR Newswire)
21.07.21	Roche bekommt für Venclexta-Kombination Breakthrough-Therapy-Status (Dow Jones)
21.07.21	AbbVie: Venetoclax Gets FDA's Breakthrough Therapy Designation In Higher Risk MDS (RTTNews)
21.07.21	Venetoclax (VENCLEXTA®) Granted US FDA Breakthrough Therapy Designation (BTD) in Higher Risk Myelodysplastic Syndrome (MDS) (PR Newswire)
20.07.21	Allergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the 2021 ASCRS (American Society of Cataract and Refractive Surgery) Annual Meeting (PR Newswire)
16.07.21	Lilly : FDA Delays Review Of Baricitinib SNDA On Atopic Dermatitis (RTTNews)
16.07.21	AbbVie : FDA Didn't Meet PDUFA Action Date For SNDA Of RINVOQ On Atopic Dermatitis Treatment (RTTNews)
16.07.21	AbbVie Provides Update Regarding RINVOQ® (upadacitinib) for the Treatment of Moderate to Severe Atopic Dermatitis in the U.S. (PR Newswire)
15.07.21	Erste Schätzungen: AbbVie mit Zahlen zum abgelaufenen Quartal (finanzen.net)
07.07.21	AbbVie to Host Second-Quarter 2021 Earnings Conference Call (PR Newswire)
29.06.21	AbbVie Says Phase 3 Ulcerative Colitis Maintenance Study Met Primary Endpoint - Quick Facts (RTTNews)
29.06.21	Upadacitinib (RINVOQ®) Met the Primary and All Secondary Endpoints in the 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients (PR Newswire)
28.06.21	AbbVie Gastroenterology Pipeline to be Featured at the 16th Congress of European Crohn's and Colitis Organisation (ECCO) (PR Newswire)
25.06.21	FDA Won't Meet PDUFA Dates For AbbVie' RINVOQ In Psoriatic Arthritis & Ankylosing Spondylitis (RTTNews)
25.06.21	AbbVie Provides Update Regarding RINVOQ® (upadacitinib) in Psoriatic Arthritis and Ankylosing Spondylitis in the U.S. (PR Newswire)
25.06.21	AbbVie's RINVOQ Gets Positive CHMP Opinion For Atopic Dermatitis Treatment (RTTNews)
25.06.21	CHMP Recommends Approval of RINVOQ® (upadacitinib) for the Treatment of Atopic Dermatitis (PR Newswire)
24.06.21	AbbVie Exercises Right To Buy TeneoOne And Lead Asset TNB-383B (RTTNews)
24.06.21	AbbVie Exercises Right to Acquire TeneoOne and Lead Asset TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple Myeloma (PR Newswire)
24.06.21	Biotech Stocks Facing FDA Decision In July 2021 (RTTNews)
18.06.21	AbbVie Declares Quarterly Dividend (PR Newswire)
12.06.21	IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows Superior Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in First-line Chronic Lymphocytic Leu... (PR Newswire)
11.06.21	AbbVie: 4-year Follow-up Analysis Of Phase 3 Venetoclax Trial Continues To Show Longer PFS In CLL (RTTNews)
11.06.21	New Data Shows AbbVie's VENCLYXTO®/VENCLEXTA® Fixed Duration Combination Demonstrates Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients after Three Years off Treatment (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

11.11.24		Börse New York in Grün: S&P 500 zum Handelsende freundlich
11.11.24		Optimismus in New York: S&P 500 am Nachmittag mit Kursplus
11.11.24		NYSE-Handel: S&P 500 mittags freundlich
11.11.24		Freundlicher Handel: Börsianer lassen S&P 500 zum Start des Montagshandels steigen
02.07.24		Freundlicher Handel: S&P 500 verbucht zum Handelsende Zuschläge
02.07.24		Schwacher Handel in New York: S&P 500 beginnt die Sitzung mit Verlusten
06.05.24		S&P 500-Titel AbbVie-Aktie: Mit dieser Dividende bereitet AbbVie Aktionären eine Freude
26.04.24		Gewinne in New York: S&P 500 am Nachmittag fester

11.11.24

Börse New York in Grün: S&P 500 zum Handelsende freundlich

11.11.24

Optimismus in New York: S&P 500 am Nachmittag mit Kursplus

11.11.24

NYSE-Handel: S&P 500 mittags freundlich

11.11.24

Freundlicher Handel: Börsianer lassen S&P 500 zum Start des Montagshandels steigen

02.07.24

Freundlicher Handel: S&P 500 verbucht zum Handelsende Zuschläge

02.07.24

Schwacher Handel in New York: S&P 500 beginnt die Sitzung mit Verlusten

06.05.24

S&P 500-Titel AbbVie-Aktie: Mit dieser Dividende bereitet AbbVie Aktionären eine Freude

26.04.24

Gewinne in New York: S&P 500 am Nachmittag fester

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu AbbVie Inc

Aktien Top/Flop

AbbVie Peer Group Nachrichten

Meistgelesene Nachrichten